Dr. Michael Dinerman's holdings in Viking Therapeutics reflect a dynamic engagement with the market. In 2019, his insider trading transactions ranged from about $4.92 million to $5.81 million, showcasing his deep belief in the stock’s potential post-IPO. However, following his...

Dr. Michael Dinerman's holdings in Viking Therapeutics reflect a dynamic engagement with the market. In 2019, his insider trading transactions ranged from about $4.92 million to $5.81 million, showcasing his deep belief in the stock’s potential post-IPO. However, following his resignation in late 2015, the nature of his stock ownership changed, as no stock awards vested after his departure, reflecting a significant drop in his direct equity stake. Fast forward to early 2024, his trading activity surged, peaking at an astonishing $55.21 million, indicating that although he left official duties in the company, his financial interests remained tied closely to Viking's performance. The variance in his holdings suggests that he was not just a passive observer but actively involved in trading, likely responding to market developments. His stake fluctuated significantly, underlining both his strategic insights and the volatile nature of biotech investments.